Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Ono Pharmaceutical
- 22 Jan 2018 Planned End Date changed to 1 Oct 2019.
- 21 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2019.
- 16 Jan 2017 Status changed from recruiting to active, no longer recruiting.